Date | Title | Description |
09.05.2024 | Optinose Announces $55 Million Registered Direct Offering | - |
25.04.2024 | Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million | Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) an... |
25.04.2024 | Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million | - |
07.03.2024 | Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights | - |
27.07.2023 | Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million | - |
02.11.2022 | OmniAb Announces Completion of Spin-Off and Business Combination | Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics
Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq
EMERYVILLE, Calif. (November 1, 2022) – OmniAb, Inc. (NASDAQ: OABI) today announced the co... |
18.11.2021 | Optinose Announces Closing of $46.0 Million Public Offering of Common Stock | YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced unde... |
18.11.2021 | Optinose Announces Closing of $46.0 Million Public Offering of Common Stock | YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced unde... |
28.07.2021 | Optinose : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million (Form 8-K) | Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to ... |
28.07.2021 | Optinose : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million | Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020
Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million
Conference Call and Webcast to be held August 11, 2021 at 8:00 ... |
29.09.2020 | New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays | |
11.06.2018 | How early retail health clinics set the stage for today’s mega-mergers | Fifteen years ago, we launched Take Care Health Systems, a pioneering company in retail health clinics. Little did we know that our clinics, and similar ones that followed, would become an important component of the current merger and acqui... |
17.10.2017 | Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock | Yardley, PA, Oct. 17, 2017 – OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today ann... |
13.10.2017 | Term Sheet — Friday, October 13 | SECRETS & MONEY
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Outcome installs video screens in doctors’ offices and charges pharmaceutical companies to run ads on them aimed at patient... |
04.10.2017 | Term Sheet — Wednesday, October 4 | 5 QS WITH A DEALMAKER
Ryan Sweeney, a general partner at Accel, joined the firm in 2008 to focus on growth investments. He became the first outside investor and board member at enterprise software companies including Atlassian, Qualtrics, ... |
19.09.2017 | Term Sheet — Tuesday, September 19 | VCs VERSUS ICOs
Companies have raised more than $1.7 billion through initial coin offerings this year, surpassing early-stage VC funding for Internet companies. It’s easy to see why an ICO is appealing to tech founders (No due diligence! LO... |
18.09.2017 | Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps | XHANCE uses Optinose® Exhalation Delivery System to uniquely deposit a proven steroid in areas of inflammation deep in the nose
FDA approval based on five clinical trials evaluating over 1,500 adult patients
Availability in the U.S. expecte... |
10.05.2017 | Term Sheet — Wednesday, May 10 | POLITE AND HOSPITABLE
New money: Obvious Ventures has officially closed its second fund with $191,919,191 million in commitments. (A filing from last month revealed a first close.) The firm’s first fund featured a numeric joke – it had $123... |
09.05.2017 | OptiNose Raises $37 Million in Series D Funding Led by Fidelity | Yardley, PA, May 9, 2017 – (Business Wire) – OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company wi... |
09.05.2017 | OptiNose Raises $37M in Series D Funding | OptiNose, a Yardley, Pa.-based commercial-stage ENT / Allergy specialty pharmaceutical company, closed a $37m Series D financing.
The round was led by Fidelity Management and Research Company with participation from Avista Capital Partners,... |
09.05.2017 | OptiNose Raises $37 Million in Series D Funding Led by Fidelity | YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with participati... |
28.01.2016 | OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology | Yardley, PA, January 28, 2016 – OptiNose, a privately-held specialty biopharmaceutical company, today announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA) approve... |
07.10.2015 | Daily funding roundup - October 7, 2015 | AppDirect raised $140M; CampoRico Fertilizers secured $40M; OptiNose nabbed $30M
TNI medical AG, a Würzburg, Germany-based medical device company, raised €3 million ($3.36 million) in venture capital funding. Pathena Fund made the investmen... |
07.10.2015 | OptiNose Closes $30M Financing Round | OptiNose, a Yardley, PA- Oslo, Norway- and London, UK-based specialty biopharmaceutical company, closed a $30M round of financing.
Backer included Avista Capital Partners, WFD Ventures and Entrepreneurs Fund LP.
The company intends to use t... |
24.09.2015 | OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-375 | Yardley, PA, September 24, 2015 – OptiNose today announced positive results from a second phase III pivotal trial, NAVIGATE I. This follows and helps both to confirm and support the positive results from a first pivotal trial, NAVIGATE II, ... |
15.07.2015 | New drug delivery methods are making taking medicine easier for everyone | Three dimensional printing technology is becoming more and more popular, from creating prosthetics to artificial organs. That same technology is also being used to create a new way to deliver medication.
Aprecia Pharmaceuticals in Langhorne... |
24.06.2015 | Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps | Yardley, PA, June 24, 2015 – (Business Wire)
OptiNose today announced positive results from its first phase III controlled clinical trial, NAVIGATE II, evaluating the safety and efficacy of OPN-375, an investigational treatment for nasal p... |
04.08.2014 | OptiNose Completes Series C-1 Financing Round | OptiNose, a Yardley, PA (USA)-based specialty pharmaceutical company, completed a Series C-1 round of financing.
Founded in 2000 and led by Peter Miller, Chief Executive Officer, OptiNose has developed AVP-825, a product that, once approved... |
04.08.2014 | OptiNose Completes Series C-1 Financing |
YARDLEY, PA, Specialty pharmaceutical company, announced today that it has completed a Series C-1 round of financing led by existing investors.
>> Click here for more funding data on OptiNose
>> To export OptiNose funding da... |
03.07.2013 | Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment | A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in Phase 3 development to treat migraine headac... |
08.06.2010 | OptiNose Receives $48.5m Equity Investment from Avista Capital Partners | OptiNose, a Yardley, PA-based developer and provider of an innovative nasal drug delivery system that achieves deep sites that are poorly accessed by existing nasal sprays, has received a $48.5m equity investment from Avista Capital Partner... |
- | Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares | YARDLEY, Pa., June 11, 2018 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 75... |
- | OptiNose Raises $37 Million in Series D Funding Led by Fidelity | YARDLEY, PA, May 9, 2017 – OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with participation f... |
- | Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment | A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in Phase 3 development to treat migraine headac... |
- | Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal | YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Ph... |
- | New Data Show Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose’s Novel Delivery Technology | Results Further Demonstrate Efficacy Potential of OptiNose Technology Across Multiple Conditions
Yardley, PA, October 20, 2010 – Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when deli... |
- | New Drug Application Submitted for Migraine Treatment Using OptiNose Technology | AVP-825 uses novel Breath Powered™ drug delivery to treat migraine
Yardley, PA, January 30, 2014 – A New Drug Application (NDA) was submitted on Monday January 27, 2014 to the U.S. Food and Drug Administration for AVP-825, a product using ... |
- | New drug delivery methods are making taking medicine easier for everyone | Whether it’s a child unable to swallow a pill or someone who has a strong fear of needles, getting the right medication to the right person can sometimes be a bit more difficult than you think it should be.
Needle fearers and anti-pill advo... |
- | Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania | YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinosewas named the Emerging Company ... |